Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Peptic ulcer (duodenal ulcer) Age: Adult |
Dose: Oral – 30 mg Frequency: once daily in the morning Duration: up to 4 weeks |
|
Indication: Peptic ulcer (gastric ulcer) Age: Adult |
Dose: Oral – 30 mg Frequency: once daily in the morning Duration: up to 8 weeks |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Gastro-oesophageal reflux disease Age: 1-11 years |
Dose: Oral – 15 mg Frequency: once daily Duration: up to 12 weeks Note: in the morning |
|
Indication: Gastro-oesophageal reflux disease Age: 1-11 years |
Dose: Oral – 30 mg Frequency: once daily Duration: up to 12 weeks Note: in the morning. May increase doses up to 30 mg twice daily if patient is still symptomatic after 2 or more weeks of treatment. |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment |
Dose: Tablet – No dosage adjustment needed Note: Renal impairment: No dosage adjustment needed. |
Administration
- Take on empty stomach
- Take before meals
Side Effect
- Headache (3-7%)
- Diarrhea (1-5%)
- Constipation (1-5%)
- Nausea (1-3%)
- Abdominal pain (1-3%)
- Anxiety
- Angina
- Palpitations
- Syncope
- Edema
- Anorexia
- Dry mouth
- Tenesmus
- Flatulence
- Melena
- Myalgia
- Tinnitus
- Allergic reaction
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Diuretics (Chlorothiazide, Chlorthalidone, Hydrochlorothiazide, Indapamide, Metolazone, Bumetanide, Ethacrynic acid, Furosemide, Torsemide, Amiloride, Eplerenone, Spironolactone, Triamterene), Digoxin
|
Increased risk of hypomagnesaemia
|
|
Erlotinib, Dasatinib, Lapatinib
|
May decrease plasma concentration
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Liver disease
|
Risk of hepatic encephalopathy
|
|
Severe kidney disease
|
Risk of drug accumulation
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store at 25° C.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.